Concepedia

Publication | Open Access

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom

DOIFull Paper Access

26

Citations

37

References

2014

Year

Samuel Aballéa, Khaled Maman, K. Thokagevistk, Jameel Nazir, Isaac Odeyemi, Zalmaï Hakimi, Andy Garnham, Mondher Toumi
Clinical Drug Investigation

Abstract

Mirabegron 50 mg/day is likely to be cost effective compared with tolterodine ER 4 mg/day for adult patients with OAB from a UK NHS perspective.

References

YearCitations

Page 1